Compound ID | 3409
Ribaxamase
Synonym(s): SYN-004 | SYN004 | SYN 004
| Agent Type: | Indirect acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Prevents dysbiosis |
| Target Pathogen: | Active against Clostridioides difficile; indicated for C. difficile infection |
| Description: | Beta-lactamase enzyme delivered orally to degrade beta-lactams in gastrointestinal tracts of patients undergoing antibiotic treatment for Clostridium difficile infection; a microbiome modulating agent |
| Institute where first reported: | Theriva Biologics |
| Year first mentioned: | 2016 |
| Highest development stage: | Phase 2 |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | ribaxamase |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.